For: | Brost S, Schnitzler P, Stremmel W, Eisenbach C. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol 2010; 16(43): 5447-5451 [PMID: 21086562 DOI: 10.3748/wjg.v16.i43.5447] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v16/i43/5447.htm |
Number | Citing Articles |
1 |
Bilal Toka, Aydin Seref Koksal, Ahmet Tarik Eminler, Mukaddes Tozlu, Mustafa Ihsan Uslan, Erkan Parlak. Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation. Digestive Diseases and Sciences 2021; 66(7): 2417 doi: 10.1007/s10620-020-06506-w
|
2 |
Anna Maria Spera. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. World Journal of Virology 2022; 11(5): 275-282 doi: 10.5501/wjv.v11.i5.275
|
3 |
Mohit Mittal, Ke-Qin Hu. Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection. Current Hepatology Reports 2017; 16(2): 90 doi: 10.1007/s11901-017-0339-9
|
4 |
Massimo Marignani, Elia Gigante, Paola Begini, Alfredo Marzano, Michela di Fonzo, Ilaria Deli, Sara Gallina, Maria Christina Cox, Gianfranco Delle Fave. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World Journal of Gastrointestinal Oncology 2012; 4(3): 37-45 doi: 10.4251/wjgo.v4.i3.37
|
5 |
Hans L. Tillmann, Kalliopi Zachou, George N. Dalekos. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?. Liver International 2012; 32(4): 544 doi: 10.1111/j.1478-3231.2011.02682.x
|
6 |
Canan Unal, Atakan Tanacan, Gunel Ziyadova, Erdem Fadiloglu, Mehmet S. Beksac. Effect of viral load on pregnancy outcomes in chronic hepatitis B infection. Journal of Obstetrics and Gynaecology Research 2019; 45(9): 1837 doi: 10.1111/jog.14065
|
7 |
Julien Marlet, Clément Lier, Emmanuelle Roch, Alain Moreau, Benjamin Combe, Lynda Handala, Sandrine Lefeuvre, Morgan Maugey, Laure Elkrief, Louis d’Alteroche, Pascal Potier, Denys Brand, Catherine Gaudy-Graffin. Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure. Antiviral Research 2021; 192: 105106 doi: 10.1016/j.antiviral.2021.105106
|
8 |
Ruma Rajbhandari, Raymond T Chung. Treatment of Hepatitis B: A Concise Review. Clinical and Translational Gastroenterology 2016; 7(9): e190 doi: 10.1038/ctg.2016.46
|
9 |
Hasan Tahsin Gozdas, Erkan Arpaci. Use of entecavir in hepatitis B virus reactivation of a patient with non-Hodgkin’s lymphoma. World Journal of Gastroenterology 2015; 21(35): 10251-10252 doi: 10.3748/wjg.v21.i35.10251
Abstract(1030) |
Core Tip(1096) |
Full Article(HTML)(2417)
|
Full Article (PDF)-546K(301)
|
Full Article (Word)-75K(165)
|
Peer-Review Report-82K(188)
|
Answering Reviewers-102K(172)
|
Times Cited (0)
|
Total Visits (8639)
|
Open
|
10 |
Yi-Jun Liao, Yen-Chang Li, Shou-Wu Lee, Chun-Ying Wu, Sheng-Shun Yang, Hong-Zen Yeh, Chi-Sen Chang, Teng-Yu Lee. Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up. Journal of the Chinese Medical Association 2017; 80(12): 758 doi: 10.1016/j.jcma.2017.07.009
|
11 |
Lorenzo Onorato, Mariantonietta Pisaturo, Clarissa Camaioni, Pierantonio Grimaldi, Alessio Vinicio Codella, Federica Calò, Nicola Coppola. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. Journal of Clinical Medicine 2021; 10(21): 5201 doi: 10.3390/jcm10215201
|
12 |
J.S. Koskinas, M. Deutsch, S. Adamidi, M. Skondra, M. Tampaki, A. Alexopoulou, S. Manolakopoulos, D. Pectasides. The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center. European Journal of Internal Medicine 2014; 25(8): 768 doi: 10.1016/j.ejim.2014.06.028
|
13 |
Violeta Molagic, Cristina Popescu, Catalin Tiliscan, Victoria Arama, Stefan Sorin Arama. Rapid loss of HBs antigen in patients with HBV reactivation and high level of transaminases during immunosuppressive therapy - case series. Revista Romana de Medicina de Laborator 2021; 29(1): 105 doi: 10.2478/rrlm-2020-0039
|
14 |
JIAN XU, HONG ZHU, YAQIN ZHAO, XIN WANG, YALI SHEN, WU WANG, FENG XU. Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma. Oncology Letters 2012; 4(3): 471 doi: 10.3892/ol.2012.745
|
15 |
Ramazan Idilman, Mutlu Arat. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Review of Anti-infective Therapy 2011; 9(8): 641 doi: 10.1586/eri.11.79
|
16 |
A. Marrone, N. Capoluongo, C. D'Amore, M. Pisaturo, M. Esposito, S. Guastafierro, I. Siniscalchi, M. Macera, A. Boemio, L. Onorato, L. Rinaldi, C. Minichini, L. E. Adinolfi, E. Sagnelli, L. Mastrullo, N. Coppola. Eighteen‐month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. Journal of Viral Hepatitis 2018; 25(2): 198 doi: 10.1111/jvh.12802
|
17 |
J. Sperl, S. Frankova, E. Kieslichova, M. Oliverius, L. Janousek, E. Honsova, P. Trunecka, J. Spicak. Urgent Liver Transplantation for Chemotherapy-Induced HBV Reactivation: A Suitable Option in Patients Recently Treated for Malignant Iymphoma. Transplantation Proceedings 2013; 45(7): 2834 doi: 10.1016/j.transproceed.2013.03.047
|
18 |
Jessica P. Hwang, John M. Vierling, Andrew D. Zelenetz, Susan C. Lackey, Rohit Loomba. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Supportive Care in Cancer 2012; 20(11): 2999 doi: 10.1007/s00520-012-1576-7
|
19 |
Jing Fang, Wenge Li, Min Tan, Xiangxin Peng, Zhao Tan, Wenbo Wang. Effect of different hepatitis B infection status on the prognosis of active lupus nephritis treated with immunosuppression: a retrospective analysis of 177 patients. International Journal of Rheumatic Diseases 2018; 21(5): 1060 doi: 10.1111/1756-185X.13313
|
20 |
Remzi Bestas, Kendal Yalcin. Clinical and Virological Features of Acute Hepatic Exacerbations in Patients With Chronic Hepatitis B Virus Infection. Cureus 2021; doi: 10.7759/cureus.15937
|
21 |
Harrys A. Torres, Marta Davila. Authors' reply: Current strategies in the management of hepatitis B virus reactivation. Nature Reviews Clinical Oncology 2012; 9(6): 350 doi: 10.1038/nrclinonc.2012.1-c2
|
22 |
L. Sarmati, M. Andreoni, G. Antonelli, W. Arcese, R. Bruno, N. Coppola, G.B. Gaeta, M. Galli, C. Girmenia, M. Mikulska, F. Pane, C.F. Perno, M. Picardi, M. Puoti, A. Rambaldi, V. Svicher, G. Taliani, G. Gentile. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. Clinical Microbiology and Infection 2017; 23(12): 935 doi: 10.1016/j.cmi.2017.06.023
|
23 |
Manzoor A. Wani, Jaswinder S. Sodhi, Ghulam N. Yatoo, Altaf Shah, Sajad Geelani, Showkat A. Zargar, Ghulam M. Gulzar, Mushtaq Khan, Sheikh A. Aziz. Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy. Journal of Clinical and Experimental Hepatology 2020; 10(6): 590 doi: 10.1016/j.jceh.2020.06.008
|
24 |
Fernando Bessone, Melisa Dirchwolf. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World Journal of Hepatology 2016; 8(8): 385-394 doi: 10.4254/wjh.v8.i8.385
|
25 |
Oguz Durmus, Levent Tekin, Alparslan Bayram Carli, Engin Cakar, Ali Acar, Asim Ulcay, Umit Dincer, Mehmet Zeki Kiralp. Hepatitis B virus reactivation in a Juvenile Rheumatoid arthritis patient under treatment and its successful management: a complicated case. Rheumatology International 2013; 33(5): 1345 doi: 10.1007/s00296-011-2244-9
|
26 |
Qiao Zhou, Qi Zhang, Kaiwen Wang, Ting Huang, Shaoping Deng, Yi Wang, Chunming Cheng. Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma. Pharmacological Research 2022; 178: 106181 doi: 10.1016/j.phrs.2022.106181
|